NASDAQ:RGENRepligen Stock Price, Forecast & News

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGEN stock has increased by 58.1% and is now trading at $143.89.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Repligen.

Repligen is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Repligen.

Repligen Co. (NASDAQ:RGEN) posted its earnings results on Thursday, July, 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.28 by $0.14. The biotechnology company had revenue of $87.46 million for the quarter, compared to analyst estimates of $78.11 million. Repligen had a return on equity of 5.93% and a net margin of 10.23%.
View Repligen's earnings history.

Repligen updated its FY20 earnings guidance on Thursday, July, 30th. The company provided EPS guidance of $1.24-1.29 for the period, compared to the Thomson Reuters consensus estimate of $1.13. The company issued revenue guidance of $332-340 million, compared to the consensus revenue estimate of $317.06 million.

6 equities research analysts have issued 1 year price objectives for Repligen's shares. Their forecasts range from $110.00 to $151.00. On average, they anticipate Repligen's stock price to reach $136.67 in the next twelve months. This suggests that the stock has a possible downside of 5.0%.
View analysts' price targets for Repligen.

Press coverage about RGEN stock has trended neutral on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repligen earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Repligen.

Repligen saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 2,520,000 shares, a decrease of 15.7% from the April 15th total of 2,990,000 shares. Based on an average trading volume of 590,000 shares, the short-interest ratio is presently 4.3 days. Approximately 5.3% of the company's shares are short sold.
View Repligen's Short Interest.

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Paypal (PYPL), Vertex Pharmaceuticals (VRTX), Splunk (SPLK), Trade Desk (TTD), Advanced Micro Devices (AMD) and Etsy (ETSY).

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (13.44%), Vanguard Group Inc. (8.35%), Conestoga Capital Advisors LLC (2.11%), Federated Hermes Inc. (1.30%), Marshall Wace LLP (1.22%) and Bank of America Corp DE (1.15%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen.

RGEN stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Vanguard Group Inc., Moody Aldrich Partners LLC, Tygh Capital Management Inc., Driehaus Capital Management LLC, Redwood Investments LLC, and American International Group Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr.
View insider buying and selling activity for Repligen.

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Point72 Asset Management L.P., Bank of America Corp DE, Marshall Wace LLP, Goldman Sachs Group Inc., Canada Pension Plan Investment Board, Nordea Investment Management AB, and Balyasny Asset Management LLC.
View insider buying and selling activity for Repligen.

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGEN stock can currently be purchased for approximately $143.89.

Repligen has a market capitalization of $7.55 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis. Repligen employs 548 workers across the globe.

The official website for Repligen is www.repligen.com.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]